ID   CRO-AP5
AC   CVCL_1148
SY   CRO-AP/5; CROAP5; AP5
DR   BTO; BTO:0002726
DR   CLO; CLO_0002619
DR   EFO; EFO_0002146
DR   CLDB; cl420
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473377
DR   cancercelllines; CVCL_1148
DR   Cosmic; 906806
DR   DSMZ; ACC-215
DR   DSMZCellDive; ACC-215
DR   GEO; GSM634730
DR   IARC_TP53; 21258
DR   IGRhCellID; CROAP5
DR   Progenetix; CVCL_1148
DR   Wikidata; Q54814509
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9734661;
RX   PubMed=9766492;
RX   PubMed=10784388;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=21685375;
RX   PubMed=31160637;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=CRO-AP%2f5
CC   Part of: LL-100 blood cancer cell line panel.
CC   Virology: Contains 30 to 60 copies of the human herpesvirus 8 (HHV-8/KSHV) genome per cell.
CC   Doubling time: ~35-40 hours (DSMZ=ACC-215).
CC   HLA typing: A*24:02:01,30:01:01; B*13:02:01,15:18:01; C*06:02:01,07:04:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,16:01:01; DQA1*02:01:01,02:01:01; DQB1*02:02:01,03:01:01; DRA*01:01:01,01:01:01; DRB1*07:01:01,11:01:01 (DSMZCellDive=ACC-215).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ=ACC-215
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,13
ST   D16S539: 11
ST   D18S51: 10,18
ST   D19S433: 14
ST   D21S11: 29,32.2
ST   D2S1338: 17,18
ST   D3S1358: 17,18
ST   D5S818: 12,13
ST   D7S820: 10,12
ST   D8S1179: 12
ST   FGA: 25
ST   Penta D: 11,12
ST   Penta E: 7,11
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C6915; Primary effusion lymphoma
DI   ORDO; Orphanet_48686; Primary effusion lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 30
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=9734661; DOI=10.1046/j.1365-2141.1998.00877.x;
RA   Carbone A., Cilia A.M., Gloghini A., Capello D., Todesco M.,
RA   Quattrone S., Volpe R., Gaidano G.;
RT   "Establishment and characterization of EBV-positive and EBV-negative
RT   primary effusion lymphoma cell lines harbouring human herpesvirus
RT   type-8.";
RL   Br. J. Haematol. 102:1081-1089(1998).
//
RX   PubMed=9766492; DOI=10.1038/sj.leu.2401160;
RA   Drexler H.G., Uphoff C.C., Gaidano G., Carbone A.;
RT   "Lymphoma cell lines: in vitro models for the study of HHV-8+ primary
RT   effusion lymphomas (body cavity-based lymphomas).";
RL   Leukemia 12:1507-1517(1998).
//
RX   PubMed=10784388; DOI=10.3109/10428190009148391;
RA   Carbone A., Cilia A.M., Gloghini A., Capello D., Perin T.,
RA   Bontempo D., Canzonieri V., Tirelli U., Volpe R., Gaidano G.;
RT   "Primary effusion lymphoma cell lines harbouring human herpesvirus
RT   type-8.";
RL   Leuk. Lymphoma 36:447-456(2000).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=21685375; DOI=10.1182/blood-2010-12-323659;
RA   Roy D., Sin S.-H., Damania B., Dittmer D.P.;
RT   "Tumor suppressor genes FHIT and WWOX are deleted in primary effusion
RT   lymphoma (PEL) cell lines.";
RL   Blood 118:E32-E39(2011).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//